Perrigo Company plc (PRGO) stock analysis

Healthcare · Drug Manufacturers - Specialty & Generic

From the 10-K filed 2026-02-26

How it makes money

Perrigo earns revenue by selling over-the-counter store brand products and branded self-care remedies to retailers and consumers across North America and Europe.

Retailers and consumers pay Perrigo for over-the-counter self-care remedies, spanning private-label store brands and dedicated consumer brands. In North America, the business focuses primarily on supplying store brand private-label products across categories such as upper respiratory, healthy lifestyle, and women's health, alongside select branded offerings. In Europe, sales are driven mainly by consumer brands.

Profitability depends on balancing product mix and commercial scale. Private-label store brands provide steady cash flow that funds investment into higher-margin, higher-growth branded products, while broad supply chain reach allows Perrigo to sell multiple molecules across various price points.

What protects it: the moat

Perrigo claims its competitive moat rests on extensive supply chain scale, diverse formulations, first-to-market development, and broad retail partnerships.

Management asserts that competitors are deterred by the operational complexity and scale required to produce and distribute hundreds of self-care formulations across diverse dosage forms, stock-keeping units, and geographic regions. Because Perrigo operates as both a leading store-brand supplier and a branded manufacturer, it claims an advantage in first-to-market product development, regulatory capabilities, and category-management partnerships with major retailers.

These advantages are asserted by management as competitive differentiators rather than independently verified structural barriers.

What growth costs

Perrigo must invest in global supply chain reinvention, restructuring initiatives, research and development, and promotional spending to maintain and expand earnings.

Perrigo directs capital toward ongoing efficiency programs, notably its Supply Chain Reinvention Program and Project Energize, which focus on streamlining operations, reducing complexity, and improving operating margins across its global manufacturing network.

Beyond structural programs, the business requires ongoing reinvestment in research and development to formulate new remedies, secure regulatory clearances, and bring first-to-market line extensions to retail shelves. It also reinvests cash generated by private-label store brands into advertising and marketing support for its higher-margin branded portfolio.

What could damage it

Losing key retail customers would disrupt distribution and severely shrink sales volume, directly eroding the store-brand scale supporting Perrigo's earnings.

Perrigo relies heavily on major retail partners to distribute its store-brand products and commercial brands. Because retail distribution is concentrated among major pharmacy chains, mass merchandisers, and supermarkets, a rupture with a principal customer—whether through contract loss, pricing disputes, or retailer consolidation—would immediately strip Perrigo of substantial volume.

Because private-label manufacturing relies on high capacity utilization and economies of scale to maintain low unit costs, a sudden loss of volume would impair factory utilization, compress gross margins, and eliminate the operating cash flows that subsidize branded investments and ongoing R&D.

About Perrigo Company plc

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Other companies in Drug Manufacturers - Specialty & Generic